The Effects of Zoledronic Acid on Bone Architecture in Premenopausal Women with Breast Cancer Receiving Adjuvant Combined Ovarian Suppression and Aromatase Inhibitor Therapy: A Randomised Controlled Trial.

在绝经前妇女中，一种将雌激素水平降至几乎为零的新治疗方法显著降低了乳腺癌复发的风险。然而，这可能会导致大量的骨质流失，从而导致骨折。使用一种新的成像技术（HR-pQCT），深入雌激素剥夺对绝经前妇女骨结构的影响将被研究。唑来膦酸，一种减少骨丢失的药物，预防这些不良骨作用的能力也将被检查。

In premenopausal women, a new treatment method that reduces oestrogen levels to almost zero significantly reduces the risk of breast cancer recurrence. However, this is likely to cause substantial bone loss leading to fractures. Using a new imaging technique (HR-pQCT), the effects of profound oestrogen deprivation on bone structure in premenopausal women will be studied. The ability of zoledronic acid, a drug that reduces bone loss, to prevent these adverse bone effects will also be examined.